DXCM250110C80000
- 0.73
- -0.21-22.34%
DexCom Newsroom
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $89
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $86
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $115
RBC Capital Reaffirms Their Buy Rating on Dexcom (DXCM)
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $94
Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $150
Nephron Research Adjusts Price Target on DexCom to $125 From $145
DexCom Is Maintained at Buy by Citigroup
DexCom Is Maintained at Overweight by Wells Fargo
DexCom Analyst Ratings
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $94
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Announces Target Price $90
DexCom Is Maintained at Buy by Canaccord Genuity
DexCom Analyst Ratings
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $99
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90